HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, V. R. Search for Related Content PubMed PubMed Citation Articles by Adams, V. R.

VAL R. ADAMS, PHARM.D., FCCP, BCOP, is Associate Professor, University of Kentucky, College of Pharmacy, 907 Rose Street, Lexington, KY 40536-0082 (vadam0{at}email.uky.edu).

Purpose. The epidemiology, natural history, patient presentation, staging, prognosis, and treatment of colorectal cancer are described. Summary. Colorectal cancer is a common malignancy that usually is not diagnosed when it is localized because it typically is asymptomatic in the early stages. Various cancer chemotherapeutic agents with different toxicities are available, including the recently introduced recombinant humanized immunoglobulin G1 monoclonal antibodies cetuximab and bevacizumab. Chemotherapy may be used with or without surgery in patients with advanced or metastatic colorectal cancer, usually for palliation rather than a cure. The results of clinical trials suggest that patients with advanced or metastatic colorectal cancer probably should receive 5-fluorouracil (5-FU)/leucovorin, irinotecan, oxaliplatin, bevacizumab, and cetuximab at some time in the course of treatment, although the preferred combinations and sequence of these agents remain to be determined. After surgery, adjuvant chemotherapy may be used for curative purposes in patients with stage III disease and some patients with stage II disease at high risk for disease recurrence and death. Although 5-FU plus leucovorin has been the standard adjuvant therapy, clinical trials have demonstrated that adding oxaliplatin or using capecitabine alone instead is an alternative. Conclusion. Several recently introduced chemotherapeutic agents appear promising for the treatment of colorectal cancer, but additional clinical research is needed to identify the ideal combinations and sequence of these agents. Index terms: Antineoplastic agents; Bevacizumab; Capecitabine; Cetuximab; Colorectal neoplasms; Combined therapy; Drugs; Epidemiology; Fluorouracil; Irinotecan; Leucovorin; Neoplasm metastasis; Oxaliplatin; Surgery; Toxicity

 

This article has been cited by other articles:

				L. K McCluggage and J. M Scholtz Golimumab: A Tumor Necrosis Factor Alpha Inhibitor for the Treatment of Rheumatoid Arthritis Ann. Pharmacother., January 1, 2010; 44(1): 135 - 144. [Abstract] [Full Text] [PDF]

				A. Sebba Tocilizumab: The first interleukin-6-receptor inhibitor Am. J. Health Syst. Pharm., August 1, 2008; 65(15): 1413 - 1418. [Abstract] [Full Text] [PDF]